WEBINAR: Clarifying neurodegenerative disorder diagnosis with new seed amplification assay
SAAmplify™-αSYN TESTING IMPROVES DIAGNOSTIC ACCURACY FOR PATIENTS
This webinar describes the revolutionary way SAAmplify™-αSYN testing, which is offered by Mayo Clinic Laboratories in collaboration with Amprion, is improving diagnostic accuracy for patients with neurodegenerative disorders. There is no cost to attend.
SAAmplify-αSYN is the first clinically available, validated test that detects pathological α-synuclein with autopsy-confirmed accuracy — bringing unprecedented biological clarity to the diagnosis of diseases like Parkinson’s, Lewy body dementia, and Alzheimer’s.
10/29/25
Save the date
Advancing Precision Diagnostics for Neurodegenerative Disorders Using the Amprion SAAmplify™-αSYN Test
Webinar Information
Date: Wednesday, Oct. 29, 2025
Time: Noon–1 p.m. CDT
Location: Via Livestream
Presented by: Mayo Clinic Laboratories
Cost: None
Questions: Contact us at mcleducation@mayo.edu for more information.
Learning objectives
Upon completion of this activity, participants should be able to:
- Analyze the current challenges and limitations in the diagnosis and management of neurodegenerative diseases.
- Explain the specific diagnostic utility of the SAAmplify-αSYN test, including how it can improve the diagnostic approach to various neurodegenerative diseases.
- Describe the technology and performance of seed amplification assays, focusing on their ability to deliver an objective, reproducible, and sensitive result.
- Evaluate a real-world case study demonstrating the effective clinical application of the SAAmplify-αSYN test.
Intended audience
Any provider who sees patients with neurologic diseases (e.g., neurologists, behavioral neurologists, and primary care physicians, including internists and family care practitioners) as well as pathologists and laboratory directors.
Additional information
SAAmplify–αSYN, a seed amplification assay for the detection of misfolded α-synuclein in cerebrospinal fluid (CSF), is intended for patients with clinically uncertain cognitive decline or Parkinsonian syndromes. Results can help diagnose synucleinopathies, such as Parkinson’s disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease with Lewy body pathology (AD-LB), and multiple system atrophy (MSA). It is currently the only seed amplification assay commercially available to detect synucleinopathies in CSF and can accurately identify α-syn pathology before definitive symptoms appear.
Prior to the development of this assay, physicians were forced to diagnose based on clinical symptoms, missing the complex reality of mixed pathologies that define most neurodegenerative disorders.
Presenters
Chief Scientific Officer for Mayo Collaborative Services
Bio
Dr. Binnicker is the chief scientific officer of Mayo Clinic Laboratories, has served as the director of the Clinical Virology and Clinical Microbiology Molecular Laboratories, and is a professor of laboratory medicine and pathology at Mayo Clinic. As chief scientific officer, Dr. Binnicker spearheads the scientific endeavors of Mayo Clinic Laboratories and leads product research, design, and development initiatives. He also works closely with leaders in Mayo Clinic's Department of Laboratory Medicine and Pathology, with other independent clinical laboratories, and leading diagnostic manufacturers to provide advanced testing and pathology services for healthcare organizations.
Assistant Professor of Neurology at Mayo Clinic
Bio
Dr. McCarter is a neurologist with subspecialty interest in neurodegenerative dementias and sleep disorders. His clinical and research interests include diagnosis and management of neurodegenerative conditions causing cognitive impairment, including dementia with Lewy bodies, Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, and corticobasal degeneration.